Trial Profile
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of glyburide in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2011
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 22 Jun 2011 New trial record